DUBUQUE, IOWA, August 18, 2023 — MedOne Pharmacy Benefit Solutions, a performance-based PBM serving employers nationwide, has integrated with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to provide its members with easy access to more cost-effective medications.
Effective August 18, MedOne members will have access to pricing and rates per Cost Plus Drugs' pharmacy and, when utilized, all patient spend will track to the patient's deductible and out-of-pocket maximum.
Committed to providing a better benefit experience, MedOne's pass-through approach to PBM aligns with Cost Plus Drugs’ completely transparent philosophy. Just as MedOne passes all upside through to its clients, Cost Plus Drugs cuts out the middleman and negotiates directly with manufacturers to obtain the best possible prices, passing along those savings to the end patient. This results in easy access to safe, affordable medications for anyone who needs them in an industry historically layered with extra costs and price inflation.
“As a practicing physician I saw first-hand the danger of patients not taking their medications because they couldn't afford them,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “I founded the Mark Cuban Cost Plus Drug Company to help solve this problem and provide a way for patients to receive their medication at an affordable price."
Notably, MedOne members can now access YUSIMRY™, a biosimilar of HUMIRA®, through Cost Plus Drugs for more than 90% less than the list price of HUMIRA®. MedOne covers YUSIMRY™ as a preferred medication and it is available to MedOne clients and members for $569.25 plus dispensing and shipping fees.
"We support a future where pharmacies and manufacturers are able to set their own prices, which are extended to plans and patients without adjustment. We can’t accomplish this alone and we are excited to collaborate with Cost Plus Drugs.
Wes Hartig, CEO of MedOne.
"We view it as our job to embrace innovators like Cost Plus Drugs and empower plans and patients to make the best choices,” said Wes Hartig, CEO of MedOne.
Transparent and pass-through since 1999, MedOne's performance-based approach to PBM includes guaranteed results for its plan sponsor clients. MedOne goes at-risk to ensure all financial guarantees are met. Layering in the relationship with Cost Plus Drugs provides additional savings for both the plan sponsor and member.
"We already offer transparent, low prices to cash-pay consumers and are excited to now be working with PBMs like MedOne to further reduce the cost to patients, and to keep the patient record complete from both a clinical and financial perspective," said Oshmyansky.
To learn more about the MedOne model, please contact sales@medone-rx.com.